A federal panel refused Gilead Science’s request to invalidate the CDC’s patents on HIV drugs, STAT reported. The CDC owns four patents for PrEP, which is the use of antiretroviral drugs to keep HIV ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for ...
– Positive Opinion Also Received for EMA’s EU-M4all Procedure, Designed to Facilitate Availability in Low- and Lower-Middle-Income Countries – The CHMP also adopted a positive EU-Medicines for all (EU ...
(RTTNews) - Gilead Sciences (GILD) announced that the FDA has accepted its New Drug Application submissions for lenacapavir-the twice-yearly injectable HIV-1 capsid inhibitor-for the prevention of HIV ...
Kenilworth, N.J.-based Merck & Co. received $2.54 billion in royalties on Thursday through a patent lawsuit against Gilead Sciences’ best-selling hepatitis C drugs Sovaldi and Harvoni, reports Reuters ...
– Gilead Also Recently Submitted Applications for Lenacapavir for PrEP to the European Medicines Agency That Will Be Reviewed Under Accelerated Assessment Review Timeline – FOSTER CITY, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback